JANX
Work Here?
Overview
About JANX
Simplify's Rating
Why JANX is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Consulting
Industrial & Manufacturing
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Parma, Ohio
Founded
1981
Get referred to JANX
See people who can refer or advise you
Simplify's Take
What believers are saying
- JANX007 kept enrolling in 1b and combination darolutamide cohorts through August 2026.
- JANX014 started Phase 1 in April 2026, expanding prostate-cancer shots on goal.
- JANX011 autoimmune dosing and JANX013 clinic entry are both slated for 2026.
What critics are saying
- Janux discontinued JANX008 in May 2026, proving preclinical promise still dies in clinic.
- BMS can terminate for convenience, leaving Janux exposed if priorities shift.
- JANX007 remains pre-approval; a weak 2027 readout would crush the prostate franchise.
What makes JANX unique
- Janux's TRACTr and TRACIr platforms localize T-cell activation to tumors, reducing off-target exposure.
- BMS signed Janux in January 2026, validating its solid-tumor targeting chemistry.
- Janux kept $970.9 million cash and investments at June 30, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
There are no jobs for JANX right now.
Find jobs on Simplify and start your career today
We update JANX's jobs every few hours, so check again soon! Browse all jobs →
About JANX
Simplify's Rating
Why JANX is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation
Industries
Consulting
Industrial & Manufacturing
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Parma, Ohio
Founded
1981
There are no jobs for JANX right now.
Find jobs on Simplify and start your career today
We update JANX's jobs every few hours, so check again soon! Browse all jobs →